Ageing increases the incidence of neurodegenerative diseases and stroke leading to severe deficits in life quality. The loss of neuronal populations in the brain is caused by various stressors and the ageing process itself. We have set up unique models and experimental tools (e.g. ischemia models, primary and human in vitro cell culture models, various Parkinson’s disease models, lentivirus and adeno-associated virus (AAV) vectors, CRISPR-Cas9, etc.) enabling search for novel ways to protect and restore neuronal networks. Our ultimate goal to develop novel treatments for diseases such as stroke and Parkinson’s disease. Using our extensive experience in established in vivo and in vitro models, we study novel drugs, neurotrophic factors, and non-coding RNAs with neuroprotective and neurorestorative properties. We utilize cutting edge in vivo models and also develop novel in vivo neurodegeneration models with virus- and CRISPR-Cas9-mediated transgenesis aiming to better approximate of clinical conditions and to study related disease-modifying processes. Using unique models on primary cells, we study the potential of neural stem cells and astrocytes to acquire neuronal phenotype, replace and restore lost neurons.
In vivo, In vitro, Molecular biology, histology and biochemical assays
We have established an extensive and unique set of in vivo and in vitro tools to study neurodegeneration. We collaborate and provide service to academia and companies. We offer consulting and experiment design, custom made experiments, data analysis, and research reports.
Extensive expertise in using AAV (including Cre-dependent vectors) and lentiviral vectors in vivo, , MicroRNA and mRNA expression analysis